DaVita Q4 Revenue Up 10%; Announces Strategic Investment In Elara Caring

DaVita reported Q4 revenue of $3.620 billion (vs. $3.295B prior year) with operating income of $561M and adjusted operating income of $586M; diluted EPS from continuing operations was $2.94 (adj. $3.40). Full-year 2025 revenue was $13.643B (vs. $12.816B), adjusted operating income rose to $2.094B and adjusted diluted EPS increased to $10.78 (reported diluted EPS $9.51); management guided 2026 adjusted operating income roughly in line at $2.085B–$2.235B but raised adjusted diluted EPS guidance sharply to $13.60–$15.00. The company repurchased 12.7M shares at an average $140.09, and announced a strategic investment with Ares in Elara Caring to expand home-based kidney care, indicating a mix of capital returns and M&A-driven growth initiatives that help explain the favorable market reaction.

Analysis

Market structure: DaVita (DVA) is a clear near-term winner — higher 2025 revenue, rising adjusted EPS and a pronounced push into home-based care with Elara should re-price expectations for durable revenue mix shift from in-center to home. Competitors with large in-center footprints (e.g., Fresenius Medical Care - FMS) face margin pressure if payors shift to home care; suppliers of medical disposables and labor-intensive services may see cost inflation. On cross-assets, DVA equity should tighten credit spreads and raise healthcare-services IV; limited FX/commodity impact outside increased medical-supply demand and wage-driven inflation in labor markets.

Risk assessment: Key tail risks include Medicare/Medicaid reimbursement cuts, adverse regulatory review of the Elara transaction, or clinical/legal events that could force conservatively sized provisions — any of which could erase the implied jump to $13.60–$15.00 adj EPS for 2026. Immediate (days) risk: pre-market gap reversal; short-term (weeks–months): deal approval and analyst revisions; long-term (quarters/years): execution of home-based kidney-care at scale and labor-cost trajectory. Hidden dependencies include Ares (ARES) financing terms, payor contracting cadence and workforce availability; catalysts to watch: CMS guidance, transaction close timing (expected later 2026), and next quarterly cadence.

Trade implications: Favor tactical long exposure to DVA on pullbacks < $120 with a 6–12 month horizon aiming for $150 (≈35% upside); hedges should be used until deal approvals. Consider a defined-risk bullish option spread (buy Jan 2027 120/180 call spread) to capture upside while capping premium. Implement relative-value trade: long DVA / short FMS (1:1 dollar) for 6–12 months to express home-care share shift.

Contrarian angles: The market may be understating the execution risk and workforce cost needed to scale home care — the EPS uplift may rely on optimistic margin assumptions and buyback leverage (12.7M shares repurchased at avg $140). Management repurchases at ~$140 vs current ~$120–125 suggest either prior overvaluation or aggressive capital return strategy that could limit dry powder if costs rise. If CMS tightens home-health reimbursement or integration falters, downside could be large and fast given leverage to payor contracts and share-count dynamics.

Key Decisions for Investors

• Establish a 2–3% long position in DVA on weakness (buy tranche if price < $120; add to $110) with a 6–12 month target of $150 and a stop-loss at 15% below average entry; rationale: guidance-backed EPS lift and strategic home-care push.
• Place a defined-risk bullish options trade: buy DVA Jan 2027 120/180 call spread sized to equal 1–2% notional equity exposure (max loss = premium), to capture upside to $180 while capping downside vs naked calls.
• Implement a pair trade: long DVA / short FMS (equal-dollar, 6–12 month horizon). Target relative outperformance of 10–15%; unwind if DVA underperforms by >10% in 30 days or if CMS announces broad reimbursement cuts.
• Buy a tactical 1% position in ARES (ticker ARES) to play private-equity upside from the Elara deal; increase only upon regulatory close (monitor filings/announcements within next 90–180 days) and trim if deal faces regulatory pushback.